Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.
Peat TJ, Gaikwad SM, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S, Phyo Z, Andres M, Hughitt VK, Simpson RM, Miller MA, Girvin AT, Taylor A, Williams D, D'Antonio N, Zhang Y, Rajagopalan A, Flietner E, Wilson K, Zhang X, Shinn P, Klumpp-Thomas C, McKnight C, Itkin Z, Chen L, Kazandijian D, Zhang J, Michalowski AM, Simmons JK, Keats J, Thomas CJ, Mock BA. Peat TJ, et al. Among authors: simmons jk. Cancer Lett. 2023 Aug 1;568:216284. doi: 10.1016/j.canlet.2023.216284. Epub 2023 Jun 24. Cancer Lett. 2023. PMID: 37356470
Mouse tumor susceptibility genes identify drug combinations for multiple myeloma.
Zhang S, DuBois W, Zhang K, Simmons JK, Hughitt VK, Gorjifard S, Gaikwad S, Peat TJ, Mock BA. Zhang S, et al. Among authors: simmons jk. J Cancer Metastasis Treat. 2020;6:21. doi: 10.20517/2394-4722.2020.40. Epub 2020 Jul 26. J Cancer Metastasis Treat. 2020. PMID: 32923678 Free PMC article.
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.
Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA, Caplen NJ. Ou O, et al. Among authors: simmons jk. Cancer Lett. 2014 Nov 28;354(2):336-47. doi: 10.1016/j.canlet.2014.08.043. Epub 2014 Sep 1. Cancer Lett. 2014. PMID: 25193464 Free PMC article.
Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.
Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J, Zhang K, Gary J, Zhang S, Gaikwad S, Connors D, Watson N, Leon E, Chen JQ, Kuehl WM, Lee MP, Zingone A, Landgren O, Ordentlich P, Huang J, Mock BA. Simmons JK, et al. Mol Cancer Ther. 2017 Sep;16(9):2008-2021. doi: 10.1158/1535-7163.MCT-17-0171. Epub 2017 May 18. Mol Cancer Ther. 2017. PMID: 28522584 Free PMC article.
Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.
Gary JM, Simmons JK, Xu J, Zhang S, Peat TJ, Watson N, Gamache BJ, Zhang K, Kovalchuk AL, Michalowski AM, Chen JQ, Thaiwong T, Kiupel M, Gaikwad S, Etienne M, Simpson RM, Dubois W, Testa JR, Mock BA. Gary JM, et al. Among authors: simmons jk. Mol Cancer Ther. 2020 Oct;19(10):2221-2232. doi: 10.1158/1535-7163.MCT-19-0671. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747423 Free PMC article.
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.
Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA. Simmons JK, et al. Mol Oncol. 2014 Mar;8(2):261-72. doi: 10.1016/j.molonc.2013.11.007. Epub 2013 Dec 3. Mol Oncol. 2014. PMID: 24429254 Free PMC article.
Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex.
Calabrese DR, Chen X, Leon EC, Gaikwad SM, Phyo Z, Hewitt WM, Alden S, Hilimire TA, He F, Michalowski AM, Simmons JK, Saunders LB, Zhang S, Connors D, Walters KJ, Mock BA, Schneekloth JS Jr. Calabrese DR, et al. Among authors: simmons jk. Nat Commun. 2018 Oct 12;9(1):4229. doi: 10.1038/s41467-018-06315-w. Nat Commun. 2018. PMID: 30315240 Free PMC article.
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klummp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas CJ, Proia DA, Kelly K. Jansson KH, et al. Among authors: simmons jk. Sci Rep. 2018 Nov 22;8(1):17239. doi: 10.1038/s41598-018-35417-0. Sci Rep. 2018. PMID: 30467317 Free PMC article.
46 results